Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02708641
Title A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients 60 With AML
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Michael Boyiadzis
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Hillman Cancer Center Pittsburgh Pennsylvania 15232 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field